Gebiet:

Advanced Glycation Endproducts (AGE): AGE-Antikörper in aktuellen Publikationen

Hier finden Sie eine Publikationsübersicht für die auf antikoerper-online.de erhältlichen -Antikörper

Publikation:

E. Nobecourt et al. (2007) The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia, Vol 50 (3) 643-653

Verwendeter Antikörper:

Methylglyoxal AGE (Arg Pyrimidin) antibody (ABIN93793)

Publikation:

Wihler et al (2005) Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition. Diabetologia, Vol 48 (8) 1645-1653

Verwendete Antikörper:

(N Epsilon) Carboxymethyl Lysin (CML) antibody (ABIN93683)

3 DG Imidazolon (AGE) antibody (ABIN93622)

Pentosidin (Advanced Glycation End Products) antibody (ABIN93823)

Publikation:

Schwenger et al (2006) Damage to the Peritoneal Membrane by Glucose Degradation Products Is Mediated by the Receptor for Advanced Glycation End-Products. J Am Soc Nephrol 17: 199-207

Verwendete Antikörper:

(N Epsilon) Carboxymethyl Lysin (CML) antibody (ABIN93683)

Publikation:

Mustafa F. Usta et al (2006) The Breakdown of Preformed Advanced Glycation End Products Reverses Erectile Dysfunction in Streptozotocin-Induced Diabetic Rats: Preventive Versus Curative Treatment. The Journal of Sexual Medicine 3 (2), 242–252.

S. Cellek et al (2004) Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: A new insight into selective nitrergic neuropathy in diabetes

Verwendete Antikörper:

Advanced Glycation End Products (AGE) antibody (0,2 mg) (ABIN93627)

Advanced Glycation End Products (AGE) antibody (1 mg) (ABIN108537)